Abstract:BACKGROUND:Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood.METHODS:For a comprehensive analysis of the tumor microenvironment in cholangiocarcinoma, we performed multiplex immunohistochemistry with two 15-marker immune panels and Nanostring assays for a comprehensive analysis of 104 surgically resected cholangiocarcinomas including intrahepatic, hilar, and distal cholangiocarcinoma. We also validated some key findings with a batch integration analysis of published single cell RNA sequencing data.RESULTS:This study found that natural killer cells occupy the largest immune cell compartment in cholangiocarcinoma. Granzyme-B+CD8+ effector T cells are significantly associated with better overall survival in both intrahepatic and distal cholangiocarcinoma. Above 85% of intrahepatic cholangiocarcinomas with higher density of PD-1-EOMES-CD8+ effector T cells are associated with long-term survival. However, only the density of PD-1-EOMES-CD8+ T cells in the tumor areas, but not in the peripheries of the tumors, is prognostic. In all three cholangiocarcinoma subtypes, T regulator cells are significantly associated with a poor prognosis; however, M1 and M2 tumor-associated macrophages or PD-L1+ tumor-associated macrophage demonstrate different prognostic values. Combining PD-L1+ M1 or M2, PD-L1- M1 or M2 tumor-associated macrophages, and T regulator cells to subgroup intrahepatic and distal cholangiocarcinoma, the prognosis is significantly better distinguished. Moreover, PD-L1- M2 tumor-associated macrophages is associated with a good prognosis in intrahepatic and distal cholangiocarcinoma, suggesting this subtype of M2 tumor-associated macrophages may be antitumoral. Interestingly, lower densities of various types of immunosuppressive cells are associated with decreased infiltration of effector T cells in distal and hilar cholangiocarcinoma, but not in intrahepatic cholangiocarcinoma. In intrahepatic cholangiocarcinoma, PD-L1+ tumor-associated macrophages exert their immunosuppressive function likely through promoting T cell exhaustion.CONCLUSIONS:This study suggests that the densities of Granzyme-B+CD8+ effector T cells and non-exhausted PD-1-EOMES-CD8+ T cells and the PD-L1 status in the tumor-associated macrophages are prognostic makers in cholangiocarcinomas. The study also supports targeting PD-L1+ tumor-associated macrophages as the immunotherapy for cholangiocarcinoma.

Research Progress of Chinese Medicine Monomers in Treatment of Cholangiocarcinoma

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma

Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers

Advances in targeted therapy of cholangiocarcinoma

Progress in molecularly targeted therapy for cholangiocarcinoma

Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches

Current Status of Pharmacological Therapy of Advanced Cholangiocarcinomas

Nano-carriers for Delivery and Targeting of Active Ingredients of Chinese Medicine for Hepatocellular Carcinoma Therapy

Immune Cell Atlas of Cholangiocarcinomas Reveals Distinct Tumor Microenvironments and Associated Prognoses.

Overcoming treatment resistance in cholangiocarcinoma: current strategies, challenges, and prospects

Immunotherapy in Cholangiocarcinoma: from Concept to Clinical Trials

Evidence for Anticancer Effects of Chinese Medicine Monomers on Colorectal Cancer

Progress in Radiotherapy for Cholangiocarcinoma

Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions

The Application Progress of Patient-Derived Tumor Xenograft Models After Cholangiocarcinoma Surgeries

Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma

Chinese Medicine in Colorectal Cancer Treatment: From Potential Targets and Mechanisms to Clinical Application

Molecular profiling reveals potential targets in cholangiocarcinoma

Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities

Molecular mechanism of Spatholobi Caulis treatment for cholangiocarcinoma based on network pharmacology, molecular docking, and molecular dynamics simulation

Unraveling the heterogeneity of cholangiocarcinoma and identifying biomarkers and therapeutic strategies with single-cell sequencing technology